Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(50.0%)
N/A
1(50.0%)
2Total
Phase 2(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT00857077Not ApplicableCompleted

Intermittent Preventive Treatment for Malaria in Infants in Navrongo Ghana

Role: collaborator

NCT00119132Phase 2Completed

Effectiveness of Intermittent Preventive Treatment for Malaria in Children

Role: collaborator

NCT02199951Unknown

Introduction of Eurartesim® in Burkina Faso, Mozambique, Ghana and Tanzania

Role: lead

All 3 trials loaded